

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
1 May 2003 (01.05.2003)

PCT

(10) International Publication Number  
**WO 03/035835 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 39/395**,  
C12P 21/08

(21) International Application Number: PCT/US02/33739

(22) International Filing Date: 22 October 2002 (22.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/337,642 25 October 2001 (25.10.2001) US  
60/347,694 9 January 2002 (09.01.2002) US

(71) Applicant: **GENENTECH, INC.** [US/US]; 1 DNA Way,  
South San Francisco, CA 94080-4990 (US).

(72) Inventor: **PRESTA, Leonard, G.**; 1900 Gough Street,  
#206, San Francisco, CA 94109 (US).

(74) Agents: **LEE, Wendy, M.** et al.; Genentech, Inc., 1 DNA  
Way, South San Francisco, CA 94080-4990 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

(88) Date of publication of the international search report:  
16 October 2003

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: GLYCOPROTEIN COMPOSITIONS

(57) Abstract: The present invention concerns compositions comprising a glycoprotein having an Fc region, wherein about 80-100% of the glycoprotein in the composition comprises a mature core carbohydrate structure which lacks fucose, attached to the Fc region of the glycoprotein. The preferred glycoprotein is an antibody or immunoadhesin.



**WO 03/035835 A3**

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/33739

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 39/395; C12P 21/08

US CL : 424/133.1; 435/326

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/133.1; 435/326

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
Please See Continuation Sheet

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KOJIMA, N. et al. Characterization of Mouse ST8Sia II (STX) as a Neural Cell Adhesion Molecule-specific Polysialic Acid Synthase J. Biol. Chem. 09 August 1996, Vol 271, No. 32, pages 19457-19463, especially Table II, and page 19460.	1, 3-4, 7, 11, 16-19 and 25
Y	DAVIES, J. et al. Expression of GnTIII in a Recombinant Anti-CD20 CHO Production Cell Line: Expression of Antibodies with Altered Glycoforms Leads to an Increase in ADCC Through Higher Affinity of FcγRIII Biotechnol. Bioeng. August 2001, Vol 74, No. 4, pages 288-294, see entire document.	6, and 14
X, P	SHIELDS, R.L. et al. Lack of Fucose on Human IgG1 N-linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity J. Biol. Chem. 26 July 2002, Vol. 277, No. 30, pages 26733-40, especially abstract.	1-39

☐ Further documents are listed in the continuation of Box C.



See patent family annex.

Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

30 April 2003 (30.04.2003)

Date of mailing of the international search report

16 JUN 2003

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Phuong Huynh

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

PCT/US02/33739

**Continuation of B. FIELDS SEARCHED Item 3:**

MEDLINE, EMBASE, BIOSIS, SCISEARCH, CAPLUS

Glycoprotein, Fc fusion, FcgammaRIII, chimeric, humanized antibody, CD20, HER2, VEGF, CD40

**THIS PAGE BLANK (USPTO)**